Recent Company News

• 06:25 PM ET Jun 18, 2025
  

  UOB Kay Hian upgrades China biotech sector view to overweight from market weight; cites rapid innovation and sturdy product pipelines

• 11:10 PM ET Jun 02, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 11:36 PM ET Jun 04, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 07:54 PM ET Jun 04, 2025
  

  Hutchmed and Innovent Biologics notes NDA acceptance by NMPA for fruquintinib combination with sintilimab for treatment of advanced renal cell carcinoma (HK$23.70, 0.00)

• 08:15 PM ET Jun 01, 2025
  

  Hutchmed presents primary results from interim analysis of SACHI Phase III study at ASCO 2025 (HK$22.45, 0.00)

• 03:38 AM ET May 30, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 12:14 AM ET May 30, 2025
  

  StreetAccount Summary - Hong Kong unusual volume traders

• 08:12 PM ET May 22, 2025
  

  Hutchmed to present new data from several studies of discovered compounds at ASCO 2025 (HK$21.05, 0.00)